TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

HELSINKI, September 26, 2022--(BUSINESS WIRE)--TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy.

This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC). This latest trial builds on the company’s emerging data on the use of its oncolytic immunotherapy candidate TILT-123 currently in trials for several other indications where promising results of intravenous usability has motivated the expansion of the portfolio of trials.

TILT Biotherapeutics’ CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients, said, "We already have clinical trials running in Europe and the USA in several cancer types, including ovarian cancer, head and neck cancer, and melanoma. We are planning several more, one of which is this new collaboration in NSCLC with our collaborator MSD. Overall, our armed oncolytic viruses are showing potential in the clinic to increase the anti-tumor benefits of checkpoint inhibitors for a range of cancers where there is a pressing need for better therapies."

The heart of TILT’s innovative approach revolves around the use of armed oncolytic adenoviruses, using cytokines and other molecules to boost the patient’s T-cell immune response to better enable it to find and destroy cancer cells.

-Ends-

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About TILT Biotherapeutics

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company’s patented TILT® technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies.

TILT’s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase 1 clinical trials.

The Company’s pioneering approach has been recognized by industry leaders including with the Merck KGaA and Pfizer Alliance, who are collaborating to investigate TILT-123’s therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio®), in Head and Neck cancer (NCT05222932). The Company also has a collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, investigating TILT-123 in combination with pembrolizumab (KEYTRUDA®) in Ovarian Cancer (NCT05271318). In 2019, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.

Based in Helsinki, Finland, the company was established in 2013 as a spin-out from the University of Helsinki. It has funding from Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, and the European Innovation Council (EIC).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005002/en/

Contacts

TILT Biotherapeutics
CBO Aino Kalervo
aino@tiltbio.com

Scius Communications
Katja Stout
+447789435990
katja@sciuscommunications.com